Our target portfolio is focused on exploring the untapped potential of Fexofenadine. It comprises six drug concepts potentially covering up to 12 indications. The exploration of Fexofenadine as an untapped resource in clinical practice is just the start of our passion for DRPx innovation. FexoTopic (OP2101) is a lotion under development for treatment of mild and moderate Atopic Dermatitis, also called Eczema. For further information on FexoTopic and our drug concept pipeline, please provide your contact details in the "Contact Us" form and we will be happy to make a personal presentation.